ArticleUrologic oncology2021
Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer.
Article in Urologic oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 35 citations in OpenAlex.
- Trends in the Adoption of MRI Associated Biopsy for Active Surveillance Within the First Year After Localized Prostate Cancer Diagnosis: A SEER-Medicare Cohort Study.Cancer medicine · 2026Article
- The Robosling Technique in Robotic Radical Prostatectomy Promotes Early and Sustained Return of Continence in Elderly Patients.Research and reports in urology · 2026Article
- Fee cuts for radiology and low-value imaging.International journal of health economics and management · 2025Article
- Benign prostatic hyperplasia during active surveillance for prostate cancer: is it time to define management strategies?Prostate cancer and prostatic diseases · 2025Review
- Sociodemographic Features, Health Care Costs, and Treatment Implications of Genomic Classifier Testing for Localized Prostate Cancer in the United States.JCO precision oncology · 2025Article
- Disparities in tissue-based biomarker testing among US Medicare beneficiaries with prostate cancer.JNCI cancer spectrum · 2025Article
- Using real-world, population-level data to assess the uptake of active surveillance for low-grade prostate cancer before and after the release of clinical guidelines.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- The 5-year results of the Stratified Cancer Active Surveillance programme for men with prostate cancer.BJU international · 2025Article
- MRI and active surveillance: thoughts from across the pond.European radiology · 2025Review
- Racial and Ethnic Variation in Receipt and Intensity of Active Surveillance for Older Patients With Localized Prostate Cancer.Urology practice · 2024Article
- Comparisons of Medical Cost Trajectories Between Non-Hispanic Black and Non-Hispanic White Patients With Newly Diagnosed Localized Prostate Cancer.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2023Observational
- How to Navigate the Treatment Spectrum from Multimodality Therapy to Observation Alone for ductal carcinoma in situ.Surgical oncology clinics of North America · 2023Review
- Racial disparities in cancer care, an eyeopener for developing better global cancer management strategies.Cancer reports (Hoboken, N.J.) · 2023Review
- Comparing Active Surveillance and Watchful Waiting With Radical Treatment Using Machine Learning Models Among Patients With Prostate Cancer.JCO clinical cancer informatics · 2023Article
- Use of expectant management based on prostate cancer risk and health status: How far are we from a risk-adapted approach?Urologic oncology · 2023Article
- Low-risk prostate lesions: An evidence review to inform discussion on losing the "cancer" label.The Prostate · 2023Review
- Employment and Labor Force Participation Among Prostate Cancer Survivors.Urology practice · 2023Article
- Prospective Implementation and Early Outcomes of a Risk-stratified Prostate Cancer Active Surveillance Follow-up Protocol.European urology open science · 2023Article
- Women's views about current and future management of Ductal Carcinoma in Situ (DCIS): A mixed-methods study.PloS one · 2023Article
- Development and External Validation of the STRATified CANcer Surveillance (STRATCANS) Multivariable Model for Predicting Progression in Men with Newly Diagnosed Prostate Cancer Starting Active Surveillance.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe treatment for men diagnosed with localized prostate cancer has changed over time given the increased attention to the harms associated with over-diagnosis and the development of protocols for active surveillance.
methodsWe examined trends in the treatment of men diagnosed with localized prostate cancer between 2004 and 2015, using the most recently available data from Surveillance, Epidemiology, and End Results Program (SEER)-Medicare. Patients were stratified by Gleason score, age, and race groups.
resultsThe use of active surveillance increased from 22% in 2004-2005 to 50% in 2014-2015 for patients with a Gleason score of 6 or below and increased from 9% in 2004-2005 to 13% in 2014-2015 for patients with a Gleason score of 7 or above. Patients with a Gleason score of 7 or above had increased use of intensity-modulated radiation therapy and prostatectomy, especially among patients aged 75 years and older. Among patients with a Gleason score of 6 or below non-Hispanic black men were less likely to undergo active surveillance than non-Hispanic white men.
conclusionsThere has been a large increase in the use of active surveillance among men with a Gleason score of 6 or below. However, non-Hispanic black men with a Gleason score of 6 or below are less likely to receive active surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.